You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
|
|---|---|
| Published in |
Clinical Cancer Research, November 2016
|
| DOI | 10.1158/1078-0432.ccr-16-0143 |
| Pubmed ID | |
| Authors |
Keith A. Lawson, Ahmed A. Mostafa, Zhong Qiao Shi, Jason Spurrell, Wenqian Chen, Jun Kawakami, Kathy Gratton, Satbir Thakur, Donald G. Morris |
| Abstract |
In addition to their direct cytopathic effects, oncolytic viruses are capable of priming anti-tumor immune responses. However, strategies to enhance the immunotherapeutic potential of these agents are lacking. Here, we investigated the ability of the multi-tyrosine kinase inhibitor and first-line metastatic renal cell carcinoma (RCC) agent, sunitinib, to augment the anti-tumor immune response generated by oncolytic reovirus. In vitro, oncolysis and chemokine production were assessed in a panel of human and murine RCC cell lines following exposure to reovirus, sunitinib or their combination. In vivo, the RENCA syngeneic murine model of RCC was employed to determine therapeutic and tumor-specific immune responses following treatment with reovirus (intra-tumoral), sunitinib or their combination. Parallel investigations employing the KLN205 syngeneic murine model of lung squamous cell carcinoma (NSCLC) were conducted for further validation Results:Reovirus mediated oncolysis and chemokine production was observed following RCC infection. Reovirus monotherapy reduced tumor burden and was capable of generating a systemic adaptive anti-tumor immune response evidenced by increased numbers of tumor-specific CD8+ IFN-γ producing cells. Co-administration of sunitinib with reovirus further reduced tumor burden resulting in improved survival, decreased accumulation of immune suppressor cells and the establishment of protective immunity upon tumor re-challenge. Similar results were observed for KLN205 tumor bearing mice, highlighting the potential broad applicability of this approach. ConclusionsThe ability to repurpose sunitinib for augmentation of reovirus' immunotherapeutic efficacy positions this novel combination therapy as an attractive strategy ready for clinical testing against a range of histologies, including RCC and NSCLC. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 29% |
| Unknown | 5 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 21% |
| Student > Ph. D. Student | 5 | 13% |
| Researcher | 4 | 11% |
| Student > Bachelor | 3 | 8% |
| Professor | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 21% |
| Immunology and Microbiology | 7 | 18% |
| Biochemistry, Genetics and Molecular Biology | 5 | 13% |
| Agricultural and Biological Sciences | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 12 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2016.
All research outputs
#6,526,441
of 23,577,654 outputs
Outputs from Clinical Cancer Research
#6,044
of 12,778 outputs
Outputs of similar age
#116,937
of 419,362 outputs
Outputs of similar age from Clinical Cancer Research
#77
of 175 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 12,778 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,362 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.